In Vivo is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

York Pharma PLC

www.yorkpharma.com

Latest From York Pharma PLC

Cardioxyl Buy To Resuscitate Bristol's CV Pipeline?

Cardiovascular

Bristol's Fibrotic Game Plan: Promedior Buy Hinges On Phase II Data

Already very active in deal-making for fibrotic disease companies and candidates in the past year, Bristol-Myers Squibb ponied up $150m in upfront cash on Aug. 31 for an option to acquire Promedior Inc. and its mid-stage biologic for myelofibrosis (MF) and idiopathic pulmonary fibrosis (IPF).

Cardiovascular Orthopedics

4Q preview: Amgen, Biogen, BMS, Celgene, Novartis, Pfizer and Roche

The full-year reporting season began on 21 January with Johnson & Johnson reporting a strong showing from pharma sales (helped from an expected short-lived boost from its hepatitis C newcomer Olysio (simeprevir). Its fourth-quarter figures already showed the effects of "currency headwinds" that are expected to impact many in its pharma peer set in 2015. It warned that foreign exchange shifts with the recent strong appreciation of the US dollar will weigh on its 2015 figures. Goldman Sachs analysts believe big US pharma companies will take a 4-6% hit from currency headwinds in 2015, with about 37-50% of the top line hit flowing to EPS.

Metabolic Disorders Cardiovascular

Verdict expected for Pfizer's palbociclib in April

The FDA has granted a priority review to Pfizer's new drug application (NDA) for palbociclib as a first-line therapy in combination with letrozole as a first-line treatment for postmenopausal women with estrogen receptor positive (ER+), human epidermal growth factor receptor 2 negative (HER2-) advanced breast cancer who have not received previous systemic treatment for their advanced disease, the firm said on 13 October.

Cardiovascular Cancer
See All

Company Information

  • Industry
  • Biotechnology
  • Pharmaceuticals
    • Specialty Pharmaceuticals
  • Therapeutic Areas
  • Dermatology
  • Infectious & Viral Diseases
  • Wound Healing & Tissue Repair
  • Alias(es)
  • Ownership
  • Public
  • Headquarters
  • Worldwide
    • Europe
      • Western Europe
        • UK
  • Parent & Subsidiaries
  • York Pharma PLC
  • Senior Management
  • Terry I Sadler, CEO
    Ian Harvey, Fin. Dir.
  • Contact Info
  • York Pharma PLC
    Phone: (44) 870 067 2563
    327 Upper 4th St.
    York House
    Milton Keynes, MK91EH
    UK
Advertisement
Advertisement
UsernamePublicRestriction

Register